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ABSTRACT The Oct-1 POU domain binds diverse DNA-
sequence elements and forms a higher-order regulatory com-
plex with the herpes simplex virus coregulator VP16. The POU
domain contains two separate DNA-binding domains joined
by a flexible linker. By protein–DNA photocrosslinking we
show that the relative positioning of the two POU DNA-
binding domains on DNA varies depending on the nature of
the DNA target. On a single VP16-responsive element, the
POU domain adopts multiple conformations. To determine
the structure of the Oct-1 POU domain in a multiprotein
complex with VP16, we allowed VP16 to interact with previ-
ously crosslinked POU-domain–DNA complexes and found
that VP16 can associate with multiple POU-domain confor-
mations. These results reveal the dynamic potential of a
DNA-binding domain in directing transcriptional regulatory
complex formation.
The human transcriptional activator protein Oct-1, which
contains a DNA-binding POU domain, displays diversity in
DNA-sequence recognition and coregulator association. The
POU domain is a bipartite DNA-binding structure made up of
two helix–turn–helix-containing DNA-binding domains: a
POU-specific (POUS) domain joined by a flexible linker to a
carboxy-terminal POU-homeo (POUH) domain (1–3). The
Oct-1 POU domain displays exceptional sequence recognition
flexibility and directs complex formation with viral and cel-
lular coregulators, including the herpes simplex virus transac-
tivator VP16 (Vmw65, aTIF) (reviewed in ref. 4).
DNA-binding studies of POU domains have revealed a high
degree of structural f lexibility in their interactions with DNA.
For example, the x-ray crystal structures of the Oct-1 and Pit-1
POU domains bound to Oct-1- and Pit-1-responsive sites,
respectively, differ: The Oct-1 POU domain binds to the
octamer sequence ATGCAAAT as a monomer, with the
POUS and POUH domains bound to opposite faces of the DNA
(2), whereas the Pit-1 POU domain binds its site as a dimer
with the POUS and POUH domains of each POU domain
bound to the same face of the DNA and with the POUS domain
in an inverted orientation to that found with Oct-1 (3).
Furthermore, combined mutagenesis of the Oct-1 or related
Brn-2 POU domains and their respective DNA targets has
provided indirect evidence that even the same POU domain
adopts different conformations on different cis-regulatory
sites, providing a mechanism for divergent sequence recogni-
tion (5, 6).
To probe directly the conformational f lexibility of the Oct-1
POU domain bound to DNA and in a higher-order complex,
we adapted a site-specific protein–DNA photocrosslinking
protocol (7) to map, individually, the locations of the POUS
and POUH domains on DNA and in complex with VP16. Our
results show that the Oct-1 POU domain adopts multiple
conformations on a single binding site and in association with
VP16.
MATERIALS AND METHODS
In Vitro Mutagenesis. The site-specific protein–DNA pho-
tocrosslinking method we used (7) involves the attachment of
the photoactivatable crosslinker 4-azidophenacyl bromide to
an appropriately positioned unique cysteine in the DNA-
binding protein. We removed the existing Oct-1 POU domain
cysteines at positions 61 of the POUS domain and 50 of the
POUH domain and introduced unique cysteines by oligonu-
cleotide-mediated site-directed mutagenesis (6). To create
unique cysteine (UC) derivatives, we made the following
POUS mutations: L23C (POUS-UC23), G24C (POUS-UC24),
F25C (POUS-UC25), G28C (POUS-UC28), D29C (POUS-UC29),
and N54C (POUS-UC54); and the following POUH mutations:
S7C (POUH-UC7), E9C (POUH-UC9), and T10C (POUH-UC10).
4-Azidophenacyl-Bromide Modification. Oct-1 POU-
domain variants were prepared in Escherichia coli as glutathi-
one S-transferase (GST)-fusion proteins essentially as de-
scribed (8). Purified POU domain was cleaved from the GST
moiety (3.5 mM in 500 ml) with thrombin and treated for 6 hr
at room temperature in the dark with 140 mM 4-azidophenacyl
bromide (Sigma) and 1.7% dimethylformamide as described
(7). Reaction mixtures were then dialyzed twice against 1 liter
of 20 mM TriszHCl, pH 8.0y200 mM KCly5% glyceroly0.1 mM
EDTA for a total of 14 hr.
POU Domain–DNA Photocrosslinking and Site-Specific
Cleavage. POU domain–DNA binding reactions (100 ml in
flat-bottomed microtiter plate wells) contained 0.28 mM Oct-1
POU domain protein, 3 3 105 cpm of the appropriate singly
end-labeled DNA probe generated by PCR amplification (see
ref. 6) in 8 mM NazHepes, pH 7.9y60 mM NaCly4 mM
spermidiney2 mM EDTAy0.2 mM DTTy0.03% Nonidet P-
40y0.1 mg/ml bovine serum albumin. Reaction mixtures were
incubated at room temperature for 30 min in the dark before
being irradiated for 1.5 min in a UV Stratalinker 2400 (Strat-
agene) with 312-nm UV bulbs. The irradiation time was
determined empirically for optimal crosslinking. After UV
irradiation, 5 ml of each binding reaction mix was removed,
added to 5 ml of SDS loading buffer, heated to 90°C for 10 min,
and subjected to 10% SDSyPAGE in the absence of a stacking
gel. Levels of crosslinking (typically 3%) were determined by
phosphorimager analysis (Fuji BAS1000). The remainder of
the sample was used to map the sites of crosslinking as
described (7). Purine cleavage patterns for each probe were
generated as described (9). DNA cleavage products were
analyzed on 20% polyacrylamidey7 M urea denaturing gels.
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Crosslinking Interference Analysis. POUS-UC54 or POUH-
UC50 was allowed to bind to the (OCTA1)TAATGARAT
probe and crosslinked to the DNA as described above except
that, after UV-induced crosslinking, E. coli-expressed GST–
VP16 and an in vitro-translated form of the VP16-induced
complex accessory factor HCF (10) were added, and the
reaction was incubated for 20 min at 37°C. The protein–DNA
complexes were separated on a native 4% polyacrylamidey
0.253 TBE gel, and bands corresponding to the VP16-induced
and POU-domain complexes were cut out of the gel, soaked in
20 mM ammonium acetate, 0.1 mM EDTA, and 2% SDS at
4°C overnight and spun through Spin-X filters (Costar). The
eluted proteinyDNA was treated as described for cleavage at
sites of crosslinking (7), and the cleavage products were
mapped by denaturing PAGE.
RESULTS
Experimental Design. Pendergrast et al. (7) have described
a site-specific protein–DNA photocrosslinking method in
which the photoactivatable crosslinking agent 4-azidophenacyl
bromide is covalently attached to a unique cysteine side chain
on the surface of a DNA-binding protein. The modified
protein is allowed to bind to DNA, and the binding reaction is
then subjected to UV irradiation, enabling the modified
cysteine side chain to form a covalent bond with nearby DNA.
Crosslinked protein–DNA complexes are then analyzed di-
rectly by SDSyPAGE or the sites of crosslinking mapped by
site-specific crosslink-induced DNA cleavage (7). We created
Oct-1 POU domains carrying either POUS- or POUH-domain-
specific crosslinkers. These domain-specific crosslinkers al-
lowed us to probe independently the positions of the two Oct-1
POU DNA-binding domains on cis-regulatory sites.
We examined Oct-1 POU-domain binding to three previ-
ously described sites (see ref. 6): the high-affinity octamer
sequence ATGCAAAT from the human histone H2B pro-
moter [for which the structure of the bound Oct-1 POU
domain is known (2)] and two VP16-responsive TAATGA-
RAT (R 5 purine) elements derived from the herpes simplex
virus ICP0 [called (OCTA1)TAATGARAT] and ICP4 [called
(OCTA2)TAATGARAT] immediate-early (IE) promoters.
These two sites represent the two different kinds of TAAT-
GARAT elements found in herpes simplex virus IE promoters
(see ref. 11); only (OCTA1)TAATGARAT elements contain
an overlapping octamer sequence (shown in bold: ATGCTA-
ATGARAT).
Fig. 1A shows a representation of the crystal structure of the
Oct-1 POU domain bound to the histone H2B octamer site (2),
with the POUS domain considered 59 of the POUH domain.
The structure of the Oct-1 POU domain on a TAATGARAT
site is not known. Mutational analysis has suggested that on an
(OCTA2)TAATGARAT site, the POUS domain lies 39 of the
POUH domain (6), and high-resolution hydroxy-radical foot-
printing of an Oct-1 POU domain–(OCTA1)TAATGARAT
complex revealed only protection of the TAAT sequence,
suggesting an unusual POU-domain conformation on this site
(12).
To generate Oct-1 POU domains with unique cysteines
suitable for protein–DNA crosslinking, we created the cys-
teine-free double mutant POUS-C61AyPOUH-C50S by replacing
the wild-type POUS-domain cysteine with an alanine and the
wild-type POUH-domain cysteine with a serine. This cysteine-
free Oct-1 POU domain binds like wild-type POU domain to
the octamer, and (OCTA1) and (OCTA2) TAATGARAT
sites (13). Directed by the structure of the Oct-1 POU domain–
octamer site complex (2), we placed unique cysteines at a
number of POUS- and POUH-domain positions that (i) were
likely not to be important for DNA binding and (ii) whose a
carbons were '9–13 Å from the DNA. The ability of these
mutant proteins to crosslink to DNA was analyzed by SDSy
PAGE. Of six POUS-domain derivatives tested (see Materials
and Methods), only POUS-UC54 crosslinked to the octamer or
(OCTA2)TAATGARAT sites effectively, and, of the four
POUH-domain derivatives tested (see Materials and Methods),
only POUH-UC7 and POUH-UC50 crosslinked effectively (data
not shown).
Fig. 1B shows the results of crosslinking POUS-UC54 and
POUH-UC7 to the octamer and the (OCTA2)TAATGARAT
sites as analyzed by SDSyPAGE in the absence of a stacking
gel. The slower migrating complexes probably represent POU-
FIG. 1. Unique cysteines in the POUS and POUH domains effec-
tive for protein–DNA crosslinking. (A) Representation (adapted from
refs. 2 and 4) of the Oct-1 POU domain–octamer site crystal structure
with the positions of the unique cysteines used for crosslinking analysis
indicated (UC54 in the POUS domain and UC7 in the POUH domain;
the precise location of UC54 is hidden behind helix 2 on the turn
between helices 3 and 4). (B) SDSyPAGE analysis of crosslinked
protein–DNA complexes after UV irradiation of POU domain-
binding reactions containing no protein (lanes 1, 4, 7, and 10),
POUS-UC54 protein (lanes 2, 5, 8, and 11), or POUH-UC7 protein (lanes
3, 6, 9, and 12). Shown are crosslinked complexes formed on the upper
and lower strands of the histone H2B octamer and the
(OCTA2)TAATGARAT sites, as indicated.
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domain crosslinked DNAs because formation of these species
depended on (i) added POU domain (Fig. 1B; a nonspecific
slower migrating species in lanes 7 and 10 formed in the
absence of POU domain), (ii) UV irradiation, (iii) modifica-
tion of the protein with 4-azidophenacyl bromide, and (iv) an
appropriately positioned cysteine (data not shown). Some
crosslinked samples produced more than one band (lanes 3, 6,
8, 9, 11, and 12), which may reflect POU-domain crosslinking
at different positions in the DNA.
The Oct-1 POU Domain Adopts Different Conformations on
the Octamer and (OCTA2)TAATGARAT Sites. Although
both strands of the octamer and (OCTA2)TAATGARAT
sites could be crosslinked to the POU domain (Fig. 1B), only
the upper strands of these probes were good substrates for
site-specific DNA cleavage (data not shown). Fig. 2 shows the
cleavage patterns that map sites of POUS- and POUH-domain
crosslinking to the upper strands of these two sites. On the
upper strand of the octamer probe, the primary site of
crosslink-induced cleavage by the modified POUS-UC54 protein
(lane 2) maps to the G at the third position of the octamer
sequence (ATGCAAAT) and is consistent with the POU
domain–octamer site crystal structure (2). The POUH-UC7
protein generated two cleavage products (Fig. 2, lane 3). These
products map to the G and C at positions 3 and 4 (ATG-
CAAAT) and are also consistent with the POU domain–
octamer site crystal structure (2).
On the (OCTA2)TAATGARAT site (Fig. 2, lanes 4–6), the
primary POUH-UC7 protein crosslink-induced cleavage (lane 6)
maps to the G just 59 of the TAATGARAT sequence (GTA-
ATGAGAT). The location of this crosslink suggests that the
TAAT sequence serves as the POUH domain-binding site the
same way the AAAT sequence does in the octamer sequence.
In contrast, the major POUS-UC54 cleavage product maps to the
opposite side of the TAAT POUH domain-binding site, at an
A immediately 39 of the GARAT sequence (TAAT-
GAGATA). Together with the POUH-domain cleavage prod-
uct, this predominant POUS-domain cleavage product pro-
vides physical evidence that the POU domain can adopt a
conformation on an (OCTA2)TAATGARAT sequence that
is very different from its conformation on an octamer se-
quence.
In addition to the major 39 POUS-domain cleavage product,
there are several minor cleavage products including one re-
sulting from a crosslink to the G four positions 59 of the TAAT
sequence (GCGGTAATGAGAT). This crosslink does not
map to the same 59 position as on the octamer site (see Fig. 2
Lower) and may result from binding of the POUS domain in an
inverted orientation as seen with Pit-1 (3) and suggested for
Brn-2 (5). The relative levels of cleavage 59 and 39 of the
TAATGARAT sequence are consistent with previous chem-
ical modification interference analyses (6, 14, 15) and muta-
tional analysis (6), which indicate that the POUS domain is
principally positioned over the GARAT element when the
Oct-1 POU domain binds to this (OCTA2)TAATGARAT
sequence.
The Oct-1 POU Domain Adopts Multiple Conformations on
an (OCTA1)TAATGARAT Site. The (OCTA1)TAATGAR-
AT site contains both octamer and (OCTA2)TAATGARAT
sequences. Differences in Oct-1 POU domain footprinting
patterns of (OCTA1)TAATGARAT sites with wild-type and
mutant GARAT sequences have suggested that the Oct-1
POU domain adopts an unusual conformation on the wild-
type site (12). We used domain-specific crosslinking to probe
this unusual conformation.
Fig. 3 shows the cleavage patterns resulting from crosslink-
ing to both strands of the (OCTA1)TAATGARAT site. The
POUH-UC7 protein crosslinked to both strands of this site just
upstream of the TAAT sequence (lanes 3 and 6), suggesting
that, on this site, the POUH domain binds uniquely to the
TAAT sequence in the same orientation as it binds to the
octamer and (OCTA2)TAATGARAT sites. In contrast, the
POUS domain crosslinked to the (OCTA1)TAATGARAT
site at several locations both 59, as on an octamer site, and 39,
as on an (OCTA2)TAATGARAT site, of the TAAT sequence
(Fig. 3, lanes 2 and 5, and Lower), suggesting that the Oct-1
POU domain adopts at least two very different conformations
on this site. In the region 59 of the TAAT POUH-domain-
binding site, the POUS domain generates two crosslink-
induced cleavages on each strand (Fig. 3, lanes 2 and 5, and
Lower). The TAAT-proximal cleavages probably reflect Oct-1
binding in an octamer-site-like conformation; the other two
cleavages may reflect an inverted POUS-domain orientation
similar to that described for the Pit-1 POU domain (3).
FIG. 2. The POUS domain is located on opposite sides of the
POUH domain on octamer and (OCTA2)TAATGARAT sites. Shown
are the cleavage products generated after crosslinking of POUS-UC54
and POUH-UC7 proteins to the upper strands of the octamer (lanes 2
and 3) and the (OCTA2)TAATGARAT (lanes 5 and 6) sites, as
indicated. Lanes 1 and 4 (A1G), purine-cleavage pattern of the probe
indicated. In lanes 2, 3, 5, and 6, uppermost bands represent uncleaved
DNA. Brackets mark the limits of the two sequences on the autora-
diographs, and arrows indicate the directionality of each consensus
motif. The two binding sites are cloned into the same plasmid in
opposite orientations. p, Cleavage product mapping to flanking
polylinker sequence, probably resulting from non-octamer-site bind-
ing. (Lower) Summary of positions of crosslink-induced cleavage.
Dashed line indicates lower-yield cleavage product.
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To examine whether the POUS domain can bind indepen-
dently either 59 or 39 of the POUH domain-binding site of the
(OCTA1)TAATGARAT sequence, we compared crosslink-
ing of the POUS-UC54 protein bound to the wild-type
(OCTA1)TAATGARAT sequence with crosslinking to two
mutant forms of the site in which either the 59 or 39 POUS
domain-binding site has been disrupted. As indicated in Fig. 4
by dots, we mutated residues in the POUS domain-binding sites
but not the precise sites of crosslinking. Consistent with
independent binding of the POUS domain to the 59 ATGC
element and the 39 GARAT element, when the GARAT
region of the (OCTA1)TAATGARAT sequence is mutated,
we only detect cleavages in the upstream ATGC portion of the
octamer site (compare lane 3 with lane 2). Likewise, when the
upstream ATGC portion of the octamer site is mutated, we
only detect cleavages near the GARAT sequence (compare
lane 4 with lane 2). These results demonstrate that two
functionally independent, but overlapping, POU domain-
binding sites make up the (OCTA1)TAATGARAT element.
These results may also explain why hydroxy-radical foot-
printing reveals a POUH-domain TAAT protection pattern but
not a POUS-domain protection pattern when the POU domain
is bound to an (OCTA1)TAATGARAT site (12). Whereas
the POUH domain apparently binds stably to the TAAT
sequence, the POUS domain can bind either upstream or
downstream of the POUH domain, thus serving as an ineffec-
tive inhibitor of hydroxy-radical attack of the sequences flank-
ing the POUH domain-binding site. Consistent with this hy-
pothesis, when the GARAT sequence is mutated, the Oct-1
POU domain effectively protects the 59 ATGC element (12).
Together, the footprinting (12) and crosslinking (this study)
results suggest that the Oct-1 POU domain structure is dy-
namic on an (OCTA1)TAATGARAT site.
VP16 Associates with Multiple Oct-1 POU-Domain Confor-
mations. The multiple conformations of the Oct-1 POU
domain on the (OCTA1)TAATGARAT site raise the issue of
how the Oct-1 POU domain is structured in a VP16-induced
complex. The structure of the VP16-induced complex is un-
clear, principally because VP16 binds DNA poorly in the
absence of Oct-1 (16, 17). Thus, although the GARAT and
neighboring 39 sequences are specifically important for form-
ing a VP16-induced complex (18–22), it is not known whether
FIG. 3. The POU domain adopts multiple conformations on an
(OCTA1)TAATGARAT site. Shown are the cleavage products gen-
erated from POU domain–DNA crosslinking to both strands of the
(OCTA1)TAATGARAT site. Lanes 2 and 3, cleavage pattern gen-
erated on the upper strand. The POUH doublet may be due to an
incomplete cleavage reaction. Lanes 5 and 6, cleavage pattern gener-
ated on the lower strand. Lanes 1 and 4 (A1G), purine-cleavage
pattern of the strand indicated. In lanes 5 and 6, the uppermost bands
represent uncleaved DNA. Brackets, arrows, and asterisk are as in Fig.
2. (Lower) Summary of positions of cleavage. Dashed lines indicate
lower-yield cleavage products.
FIG. 4. The POUS domain binds to the wild-type half-site in
mutant forms of the (OCTA1)TAATGARAT site. Shown are the
cleavage products generated from crosslinking of the POUS domain to
wild-type (lane 2) and mutant (lanes 3 and 4) (OCTA1)-
TAATGARAT sites. Lane 1 (A1G), purine-cleavage pattern of the
wild-type probe; lane 3, (OCTA1)TAATGARAT site with the mu-
tated 39 GARAT sequence (underlined), . . . ATTAGCTTC. . . (mu-
tations shown in bold); lane 4, (OCTA1)TAATGARAT site with the
mutated 59 OCTA sequence (underlined), . . . GCAAGGTA. . . (mu-
tations shown in bold). Brackets and vertical arrows are as in Fig. 2.
(Lower) Sequence with sites of mutations marked by dots and
crosslinking sites indicated. Dashed line indicates lower-yield cleavage
product.
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these sequences induce an Oct-1 POU-domain conformation
compatible with recognition by VP16 (12) or create a VP16-
binding site (see ref. 4).
To probe the conformation of the Oct-1 POU domain in a
VP16-induced complex, we devised a crosslinking strategy
analogous to chemical modification interference analysis. We
first crosslinked either the POUS or POUH domain to the
(OCTA1)TAATGARAT site and then selected those
crosslinked species that could still form a complex with VP16
(see Materials and Methods). If a particular conformation of
the POU domain is incompatible with VP16-induced complex
formation, crosslinks resulting from that conformation should
interfere with VP16-induced complex formation and be miss-
ing in the DNAs selected for VP16-induced complex forma-
tion. We refer to this strategy as ‘‘crosslinking interference
analysis.’’
Fig. 5 shows the results of the crosslinking interference
analysis with POUS- (POUS-UC54; lanes 2–4) and POUH-
(POUH-UC50; lanes 5–7) specific crosslinkers. Because the level
of POUH-UC7 cleavage on the (OCTA1)TAATGARAT site
was not sufficient for the crosslinking interference analysis
(see Fig. 3), we used the natural POUH-domain cysteine in
POUH-UC50 for this analysis. Cysteine 50 lies in the DNA-
recognition helix and contacts the DNA major groove in the
octamer cocrystal structure (2); we did not use this crosslinker
in the analyses described above to avoid crosslinker-induced
changes in POUH-domain binding to the DNA.
Because cysteine 50 is directed 39 of the octamer sequence
(2) in the Oct-1 POU-domain–octamer site crystal structure,
we expected POUH-UC50 crosslinking to occur within the
GARAT sequence. The observed crosslink-induced cleavage,
however, maps 59 of this region at the G residue in the C:G base
pair at the fourth position within the octamer sequence
(ATGCTAAT; Fig. 5, lane 5). This difference may reflect an
alteration of the precise conformation of the POUH-UC50
domain on DNA induced by (i) the different binding sites [H2B
octamer vs. (OCTA1)TAATGARAT] or (ii) the crosslinking
moiety. Whichever the case, the POUH-UC50 crosslink inter-
feres very strongly with VP16-induced complex formation
(compare lanes 6 and 7). These results demonstrate that it is
possible to interfere with VP16-induced complex formation by
crosslinking and suggest that the conformation, precise posi-
tion, or f lexibility of the POUH domain on the
(OCTA1)TAATGARAT site is critical for association of the
Oct-1 POU domain with VP16.
In striking contrast to the strong interference caused by the
POUH-UC50 crosslink, the POUS-UC54 crosslinks, either at or
near the octamer ATGC sequence (OCTA X-links) or near the
GARAT sequence (GARAT X-link), are compatible with
VP16-induced complex formation (Fig. 5, compare lanes 3 and
4). An apparent slight decrease in crosslink-induced cleavages
at the octamer ATGC sequence (compare lanes 3 and 4) may
suggest a preference for POUS-domain binding to the GARAT
sequence in a VP16-induced complex. Nevertheless, crosslink-
ing of the POUS domain to the ATGC sequence is compatible
with VP16-induced complex formation, demonstrating that
VP16 can associate with multiple conformations of the Oct-1
POU domain.
DISCUSSION
We have probed the structure of the Oct-1 POU domain on
different cis-regulatory sites and in a multiprotein complex.
The structures of DNA-bound POU domains have been
previously studied by x-ray crystallography (2, 3) and by
mutagenesis (5, 6); crystallography, however, inherently pro-
vides only a static view of macromolecular interactions, and
mutational analyses are indirect. Here, we have used protein–
DNA photocrosslinking in a domain-specific manner to probe
directly the conformation of the Oct-1 POU domain on DNA
and in the VP16-induced complex. The photocrosslinking
method we used (7) was particularly well suited for this analysis
because the crosslinker is placed at a unique position on the
protein and multiple sites of crosslinking to the DNA can be
easily mapped with end-labeled probes. The results of our
crosslinking studies of the two DNA-binding domains of the
Oct-1 POU domain on different regulatory sites revealed the
dynamic nature of Oct-1 binding to a single regulatory site—
the (OCTA1)TAATGARAT site—and crosslinking interfer-
ence revealed flexibility of the Oct-1 POU domain in VP16-
induced complex formation.
We used three different Oct-1-binding sites in our studies—
the high-affinity histone H2B octamer sequence and two
VP16-responsive elements, an (OCTA2) and (OCTA1) TA-
ATGARAT site—and each has revealed different arrange-
ments of the Oct-1 POU domain as illustrated in Fig. 6. The
pattern of crosslinking to the octamer site agrees with that
predicted by the crystal structure (2), suggesting that, in
solution, the POU-domain structure adopts the unique con-
formation elucidated crystallographically. Crosslinking to the
(OCTA2)TAATGARAT site provides physical evidence for
the unexpected structure of the Oct-1 POU domain revealed
on this site by mutational analysis (6), with the POUS domain
principally positioned over the GARAT element and thus to
FIG. 5. VP16 associates with multiple conformations of the Oct-1
POU domain. Shown are the results of a crosslinking interference
analysis of two unique-cysteine derivatives of the POU domain,
POUS-UC54 (lanes 2–4) and POUH-UC50 (lanes 5–7), crosslinked to the
lower strand of the (OCTA1)TAATGARAT site. POUS crosslinks
over the 59 ATGC (OCTA X-links) or 39 GARAT (GARAT X-link)
sequences and POUH crosslinks (X-link) are indicated. In lanes 2–7,
the uppermost bands represent uncleaved DNA. X-link (above lanes),
standard crosslinking analysis of the POU domain alone to the site;
POU, crosslinking pattern of the POU-domain complex after electro-
phoretic mobility retardation; VIC, crosslinking interference pattern
of the VP16-induced complex after electrophoretic mobility retarda-
tion.
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the opposite side of the POUH domain than when bound to the
octamer sequence. The results of crosslinking to the
(OCTA1)TAATGARAT site show that the Oct-1 POU do-
main can adopt either the octamer-like or (OCTA2)-
TAATGARAT-like conformation on the single binding site.
These results lead to the view of a dynamic Oct-1 POU domain
on an (OCTA1)TAATGARAT site: while the POUH domain
remains fixed, the POUS domain swings from one POUS-
domain-binding site to the next.
The role of the Oct-1 POUS domain in VP16-induced
complex formation—beyond its requirement for effective
DNA binding by the Oct-1 POU domain (23)—is unclear, as
is its position in the complex. It is known that the POUS
domain is not essential for VP16-induced complex formation
(16, 24); indeed, the POUS domain can be replaced by a
completely different DNA-binding module, and the resulting
chimeric ‘‘POU domain’’ can support efficient VP16-induced
complex formation (25). In the native POU domain, however,
the POUS domain may play a specific role, because mutations
in the POUS domain can have a selective effect on VP16-
induced complex formation on an (OCTA2)TAATGARAT
site (6).
The crosslinking interference analysis described here with
an (OCTA1)TAATGARAT site shows that, whether the
POUS domain lies over the OCTA element 59 of the POUH
domain or the GARAT element 39 of the POUH domain, the
Oct-1 POU domain can associate with VP16. Consistent with
these results even in a natural (OCTA1)TAATGARAT VP16-
induced complex, the POUS domain can be crosslinked by UV
irradiation to either the OCTA or GARAT sequences (un-
published results).
These results impact on our view of the VP16-induced
complex. First, because the POUS domain need not be bound
to the GARAT element to promote VP16-induced complex
formation, the essential function of the GARAT element in
VP16-induced complex formation (18–20) is probably not to
provide a binding site for the Oct-1 POUS domain. Instead, it
is more likely that the GARAT element is essential for
VP16-induced complex formation because it provides an es-
sential binding site for VP16. Second, the ability of the POUS
domain to promote VP16-induced complex formation when
crosslinked to the GARAT element suggests that VP16 and
the POUS domain can co-occupy the GARAT element. We do
not know how such co-occupancy may occur. The simple
hypothesis that VP16 and the Oct-1 POUS domain bind to
different faces of the DNA is probably not correct, because
analysis of VP16-induced complex formation with inosine-
substituted DNA probes suggests that VP16 and the Oct-1
POUS domain both recognize sequence determinants in the
major groove of the DNA (13).
In conclusion, these studies reveal an extraordinary level of
structural versatility and adaptability in how two macromole-
cules—a protein and DNA—interact with each other. As the
DNA changes structure, as in the different sequences of the
cis-regulatory sites, the protein—the Oct-1 POU domain—
responds by also changing its structure.
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FIG. 6. Model for binding of the Oct-1 POU domain to three DNA
targets, the octamer and the (OCTA2) and (OCTA1) TAATGARAT
sites, highlighting conformational f lexibility in Oct-1 POU DNA-
binding domain arrangement.
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